AveXis Announces Proposed Public Offering of Common Stock
January 16 2018 - 7:25AM
AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer
and sell, subject to market conditions, up to $400 million of
shares of its common stock in an underwritten public
offering. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or the actual size or terms of the
offering.
Goldman Sachs & Co. LLC, Jefferies LLC and BofA Merrill
Lynch are acting as joint book-running managers. BMO Capital
Markets Corp. is acting as lead manager. AveXis intends to
grant the underwriters a 30-day option to purchase up to an
additional $60 million of shares of common stock at the public
offering price, less the underwriting discounts and
commissions.
The offering will be made pursuant to a shelf registration
statement on Form S-3 that was filed by AveXis with the Securities
and Exchange Commission (“SEC”) and became automatically effective
on March 17, 2017. The offering will be made only by means of
a written prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. When
available, copies of the preliminary prospectus supplement and
accompanying prospectus may also be obtained for free from the
offices of Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282; by telephone at
1-866-471-2526; or by email at prospectus-ny@ny.email.gs.com,
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at
1-877-821-7388; or by email at Prospectus_Department@Jefferies.com,
or BofA Merrill Lynch at NC1-004-03-43, 200 North College Street,
3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department or by email at dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the applicable
securities laws of such state or jurisdiction.
About AveXis, Inc.AveXis is a
clinical-stage gene therapy company developing treatments for
patients suffering from rare and life-threatening neurological
genetic diseases. The company’s initial proprietary gene therapy
candidate, AVXS-101, is in the pivotal phase of study for the
treatment of SMA Type 1, and a Phase 1 trial for SMA Type 2. The
company also intends to expand its development of gene therapy into
two additional rare neurological monogenic disorders: Rett syndrome
and a genetic form of amyotrophic lateral sclerosis caused by
mutations in the superoxide dismutase 1 gene.
Media Inquiries:Lauren BarbieroW2O
Group646-564-2156lbarbiero@w2ogroup.com Investor Inquiries:Jim
GoffAveXis, Inc.650-862-4134jgoff@avexis.com
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
AVEXIS, INC. (NASDAQ:AVXS)
Historical Stock Chart
From Jul 2023 to Jul 2024